Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Immunosuppressants and rituximab
4 evidence topics · 4 sources
Guideline recommendation when maintenance doses are high
Pooled randomized evidence for immunosuppressants and immunomodulators
“Four trials fulfilled the selection criteria: one of azathioprine (27 participants), two of IFN beta‐1a (77 participants in total) and one of methotrexate (60 participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the trials showed significant benefit in any of the outcomes selected by their authors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the trials was large enough to rule out small or moderate benefit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate versus placebo: corticosteroid or immunoglobulin dose reduction
“14 (52%) of 27 taking methotrexate and 14 (44%) of 32 taking placebo had a greater than 20% reduction in mean weekly dose of corticosteroids or intravenous immunoglobulin (adjusted odds ratio 1.21, 95% CI 0.40-3.70).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Oral methotrexate 15 mg weekly showed no significant benefit, but limitations in the trial design and the high rate of response in the placebo group meant that a treatment effect could not be excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rituximab versus placebo: worsening after immunoglobulin discontinuation
“In this randomized, double-blind, placebo-controlled study, conducted at seven Italian hospitals, CIDP patients under immunoglobulin therapy were assigned to receive either rituximab (1 g on Days 1, 15 and 180 ± 7) or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A similar proportion of patients in both the rituximab (12/19, 63.2%) and placebo (12/18, 66.6%) groups worsened at Month 12 [odds ratio (OR) 0.86; 95% confidence interval (CI) 0.22–3.32].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to worsening was 5 months for rituximab and 2 months for placebo (Log-rank P = 0.4372).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote